Business
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results
Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"text","content":"Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT\nBURLINGAME, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today provided a business update and reported financial results for the third quarter ended September 30, 2019.\n “There continues to be strong enrollment in all three of our ongoing clinical studies and we are scheduled to present data related to each at medical meetings during the fourth quarter,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “The highlight will be the updated data from the CPI-006 study in an oral presentation at SITC in November, which will add to the biologic and clinical evidence supporting CPI-006’s unique dual-mechanisms of action, both in monotherapy and in combination with ciforadenant. We will also provide updated data supporting the potential for our Adenosine Gene Signature to serve as a biomarker capable of identifying patients that are most likely to respond to therapies targeting the adenosine pathway. In December, we will present the first clinical data on CPI-818 in patients with T-cell lymphoma.” Recent Achievements CPI-006: Immunomodulatory Anti-CD73 Antibody Continued enrollment of up to 350 patients with advanced cancer in a Phase 1/1b adaptive design clinical trial evaluating CPI-006 as a single agent and in combination with ciforadenant or pembrolizumab.Selected recommended dose of 18 mg/kg and initiated the disease expansion phase in the monotherapy arm of the study.The trial also continues to enroll patients in the dose escalation phase in the ciforadenant combination arm of the study. Ciforadenant (CPI-444): A2A Receptor Antagonist of Adenosine Continued enrollment of patients with renal cell cancer (RCC) in an amended Phase 1b/2 clinical trial evaluating ciforadenant in combination with Genentech’s Tecentriq® (atezolizumab), an anti-PD-L1 antibody. The RCC patients in the trial have failed treatments with anti-PD-(L)1 antibodies and tyrosine kinase inhibitors. This trial is also evaluating the use of a novel gene expression biomarker known as the Adenosine Signature, that may have the potential to predict patients most likely to respond to therapy and form the basis for ...